NICE nod for Lynparza in prostate cancer group without biomarker test
Lynparza (olaparib) has been recommended for use alongside abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer in UK adults who cannot or will not have chemotherapy, regardless of biomarker status.
The AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) drug has been recommended in this group in a Final Draft Guidance from the UK cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE).
"This is the first time that patients with this form of prostate cancer will be able to access a PARP inhibitor without the need for a specific biomarker test"Noel Clarke, professor of Urological Oncology at The Christie, and Salford Royal Hospitals, said: “Data from the PROpel Phase III trial show that olaparib in combination with abiraterone and prednisone or prednisolone provides real benefit for men with metastatic castration-resistant prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze